Contributions
Abstract: PB2242
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common hematologic malignancy.
Aims
This study aims to describe the real-world incidence and prevalence of MM in Israel.
Methods
A retrospective database study was conducted in Maccabi Healthcare Services (MHS), a 2-million-member health payer-provider in Israel. MM was defined by cross-linking ICD-9 diagnoses with dispensed MM treatments and free light chain assays. MM prevalence (31/12/2016) and incidence (2012-2016) rates were calculated and age-adjusted to the WHO World standard population. Prevalent patients were characterized in terms of socio-demographic characteristics, comorbidities, and medication use.
Results
The crude and age-standardized prevalence of MM was 3.2 and 2.6 per 10,000 population, respectively. The mean (± SD) age was 68.1 ± 11.0 years (55% male). The prevalence of cardiovascular disease, diabetes, hypertension, chronic kidney disease (eGFR <60) and osteoporosis were 32%, 25%, 59%, 59%, and 38%, respectively. Overall, 88.5% ever had a record of dispensed MM treatment. Among patients treated in 2016 (N=427), their last purchase consisted of 43% first line, 30% second line, 18% third line, and 9% fourth line or more. The crude and age-standardized annual incidence rate was 5.1 and 4.7 per 100,000 population, respectively. The mean age at diagnosis was 68.5 ± 11.4 (58% male). Adjusting to the Israeli population, there were an estimated 485 new cases of MM in Israel in 2016.
Conclusion
These results indicate a substantial burden of MM in Israel, in line with international estimates. This study serves as the basis for further research on MM patient outcomes.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Comorbidities, epidemiology, Multiple Myeloma, Treatment
Abstract: PB2242
Type: Publication Only
Background
Multiple myeloma (MM) is the second most common hematologic malignancy.
Aims
This study aims to describe the real-world incidence and prevalence of MM in Israel.
Methods
A retrospective database study was conducted in Maccabi Healthcare Services (MHS), a 2-million-member health payer-provider in Israel. MM was defined by cross-linking ICD-9 diagnoses with dispensed MM treatments and free light chain assays. MM prevalence (31/12/2016) and incidence (2012-2016) rates were calculated and age-adjusted to the WHO World standard population. Prevalent patients were characterized in terms of socio-demographic characteristics, comorbidities, and medication use.
Results
The crude and age-standardized prevalence of MM was 3.2 and 2.6 per 10,000 population, respectively. The mean (± SD) age was 68.1 ± 11.0 years (55% male). The prevalence of cardiovascular disease, diabetes, hypertension, chronic kidney disease (eGFR <60) and osteoporosis were 32%, 25%, 59%, 59%, and 38%, respectively. Overall, 88.5% ever had a record of dispensed MM treatment. Among patients treated in 2016 (N=427), their last purchase consisted of 43% first line, 30% second line, 18% third line, and 9% fourth line or more. The crude and age-standardized annual incidence rate was 5.1 and 4.7 per 100,000 population, respectively. The mean age at diagnosis was 68.5 ± 11.4 (58% male). Adjusting to the Israeli population, there were an estimated 485 new cases of MM in Israel in 2016.
Conclusion
These results indicate a substantial burden of MM in Israel, in line with international estimates. This study serves as the basis for further research on MM patient outcomes.
Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical
Keyword(s): Comorbidities, epidemiology, Multiple Myeloma, Treatment